TSE: 4565 - Sosei Group Corporation

Yield per half year: -26.83%
Dividend yield: 0.00%
Sector: Healthcare

Share chart Sosei Group Corporation

en.porti.ru21002100180018001500150012001200900900600600Dec '23Dec '2320242024Feb '24Feb '24Mar '24Mar '24Apr '24Apr '24May '24May '24Jun '24Jun '24Jul '24Jul '24Aug '24Aug '24Sep '24Sep '24Oct '24Oct '24Nov '24Nov '24Dec '24Dec '2420252025Feb '25Feb '25Mar '25Mar '25Apr '25Apr '25
Download SVG
Download PNG
Download CSV

About Sosei Group Corporation

Sosei Group Corporation разрабатывает биофармацевтические продукты по всему миру. Его продаваемые продукты включают Ultibro/Breezhaler и Seebri/Breezhaler для лечения хронической обструктивной болезни легких; Enerzair для лечения астмы; и ORAVI, орофарингеальный кандидоз.

more details
Ассортимент продукции компании состоит из агониста GPR35 для лечения воспалительных заболеваний кишечника и желудочно-кишечного тракта, который находится на доклинической стадии; HTL0016878 для шизофрении и других нервно-психических расстройств; PF-07081532 при сахарном диабете 2 типа и ожирении; PF-07054894 при воспалительных заболеваниях кишечника; и PF-07258669 для анорексии. Корпорация Sosei Group имеет стратегическое сотрудничество с AbbVie, Biohaven, Genentech, GSK, Takeda, Pfizer, Neurocrine Biosciences, Novartis, Verily, AstraZeneca и Takeda. Компания была зарегистрирована в 1990 году и имеет штаб-квартиру в Токио, Япония.

Див.доход ао 0.3433
Дивиденд ао 2.5
Сайт https://soseiheptares.com
Цена ао 940
Change price per day: +0.9574% (940)
Change price per week: +6.27% (893)
Change price per month: +7.23% (885)
Change price per 3 month: -7.14% (1022)
Change price per half year: -26.83% (1297)
Change price per year: -40.76% (1602)
Change price per year to date: -7.14% (1022)

Underestimation

Title Value Grade
P/S 8.88 1
P/BV 1.7 8
P/E 442.87 1
EV/EBITDA -21.01 0
Total: 3.88

Efficiency

Title Value Grade
ROA, % -4.58 0
ROE, % -10.77 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0.5 5
Total: 0.96

Debt

Title Value Grade
Debt/EBITDA -10.63 10
Total: 8

Growth impulse

Title Value Grade
Yield Revenue, % 344.81 10
Yield Ebitda, % -326.47 0
Yield EPS, % 11.19 2
Total: 3.2

ETFShare, %Profitability for 1 year, %Dividends, %
SPDR S&P International Small Cap ETF 0.04703 8.94 3.10348
Schwab International Small-Cap Equity ETF 0.0321 10.07 3.20638
Vanguard FTSE All-World ex-US Small-Cap ETF 0.02 9.39 3.09932
Direxion Daily Japan Bull 3x Shares 0.01875 6.34 2.48436
FlexShares Morningstar Developed Markets ex-US Factor Tilt Index Fund 0.00644 5.17 3.85434
SPDR Portfolio Developed World ex-US ETF 0.00296 5.29 3.28401
SPDR Portfolio MSCI Global Stock Market ETF 0.00042 17.99 2.19607
Vanguard ESG International Stock ETF 0 6.39 3.07501
0.028.73.04



Head Job title Payment Year of birth
Mr. Shinichi Tamura Founder & Chairman of the Board 233M 1949 (76 years)
Mr. Hironoshin Nomura Executive Officer, Executive VP & CFO N/A 1983 (42 years)
Mr. Kieran Johnson F.C.A. Executive Officer, Executive VP & Chief Accounting Officer N/A 1969 (56 years)
Dr. Miles Congreve Chief Scientific Officer N/A
Mr. Kazuhiko Yoshizumi Executive Officer, Executive VP & Chief Compliance Officer N/A 1954 (71 year)
Shinichiro Nishishita VP of Investor Relations & Head of Regulatory Disclosures N/A
Stacey Southall Associate Director & Head of Biophysics N/A
Ms. Candelle Chong Executive Officer, Executive VP & Chief of Staff N/A 1989 (36 years)
Mr. Christopher Cargill Representative Executive Officer, President, CEO & Director 200M 1984 (41 year)
Mr. Toshihiro Maeda Chief Operating Officer N/A

Address: Japan, Tokyo -, PMO Hanzomon - open in Google maps, open in Yandex maps
Website: https://soseiheptares.com